Marie Michele Sainvil, MD1,2, Melissa Lowe, MS3*, Delaney Underwood, MS4*, Yan Li, PhD3*, Tomi F. Akinyemiju, PhD, MS.1,5*, Taewoong Choi, MD1,6, Cristina Gasparetto, MD1,6*, Mitchell Horwitz, MD1,6, Gwynn D. Long, MD1,6*, Richard Lopez, MD1,6*, Stefanie Sarantopoulos, MD, PhD1,6, Edwin Alyea III, MD1,6*, Nelson J. Chao, MD1,6, Thomas W. LeBlanc, MD, MA, MS1,5,6, Yubin Kang, MD1,6, Suzanne Kirby, MD, PhD1,6, Chenyu Lin, MD1,6, Matthew Stuart McKinney, MD1,6, Alexandra Stefanovic, MD1,6, Jie Wang, MD, MS1,6, Andrea Sitlinger, MD1,6*, Sendhilnathan Ramalingam, MD6, Anthony D. Sung, MD7 and Sanghee Hong, MD1,6
1Duke Cancer Institute, Duke University School of Medicine, Durham, NC
2Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, durham, NC
3Duke Cancer Institute Biostatistics Shared Resource, Duke University, Durham, NC
4Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham
5Department of Population Health Sciences, Duke University School of Medicine, Durham, NC
6Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC
7Division of Hematologic Malignancies and Cellular Therapy, Kansas University, Kansas City, KS